Immune-related AEs (irAEs) affecting the biliary system on treatment with immune-oncology (I-O) agents, such PD-1/PD-L1 mAbs, are considered rare and their management remains unclear.
Gelsomino, F., Vitale, G., Ardizzoni, A. (2018). Immune-mediated cholangitis: is it always nivolumab’s fault?. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 67(8), 1325-1327 [10.1007/s00262-018-2159-3].
Immune-mediated cholangitis: is it always nivolumab’s fault?
Gelsomino, Francesco;Vitale, Giovanni;Ardizzoni, Andrea
2018
Abstract
Immune-related AEs (irAEs) affecting the biliary system on treatment with immune-oncology (I-O) agents, such PD-1/PD-L1 mAbs, are considered rare and their management remains unclear.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
